Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Ohio native Bill Lowen won the 2025 FXR Pro Fish Bassmaster Elite at Florida's St. Johns River with a total weight of 73 pounds, 14 ounces.

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

FXR Pro Fish has signed on as the title sponsor for the 2025 Bassmaster Elite at St. Johns River in Palatka, Florida. / Seigo Saito | B.A.S.S. “We are excited that FXR will be the title sponsor ...

For the First Trust Industrials/Producer Durables AlphaDEX Fund ETF (Symbol: FXR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $88.23 per unit.

MANITOBA, Calif.--(BUSINESS WIRE)--FXR Pro Fish, a brand driven by bringing innovation to the water, is proud to announce its partnership with the Bassmaster Elite series as the title sponsor for ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...